Stockscreener 앱 받기
1.89
0.53%
-0.01
전일 마감가:
$1.90
열려 있는:
$1.8605
하루 거래량:
9,729
Relative Volume:
0.04
시가총액:
$73.83M
수익:
-
순이익/손실:
$-41.36M
주가수익비율:
-1.1524
EPS:
-1.64
순현금흐름:
$-42.09M
1주 성능:
+0.53%
1개월 성능:
-3.08%
6개월 성능:
+2.16%
1년 성능:
-31.27%
1일 변동 폭
$1.85
$1.98
1주일 범위
$1.85
$2.00
52주 변동 폭
$0.8981
$3.4154
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
명칭
Armata Pharmaceuticals Inc
전화
310-655-2928
주소
4503 Glencoe Avenue, Marina del Rey, CA
ARMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.89 | 73.83M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-19 | 개시 | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals Elects Board Members at Annual Meeting - TipRanks
Chronic Pseudomonas aeruginosa Pulmonary Infections Pipeline - openPR.com
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Biotech Alert: Searches spiking for these stocks today - TipRanks
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus
Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus
Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com
Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus
Armata reports data from Phase 1b/2a diSArm trial - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times
New Strong Sell Stocks for May 8th - The Globe and Mail
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus
Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
New Strong Sell Stocks for April 24th - TradingView
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Inc (ARMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):